Literature DB >> 29957592

Up to 11 years of experience with the Melody valved stent in the right ventricular outflow tract.

Bjorn Cools1, Steven Brown, Werner Budts, Ruth Heying, Els Troost, Derize Boshoff, Benedicte Eyskens, Marc Gewillig.   

Abstract

AIMS: The aim of the study was to report up to 11 years of follow-up after Melody valve implantation in the pulmonary position. METHODS AND
RESULTS: This was a single-institution non-randomised prospective observational study of all Melody valves in the pulmonary position after discharge between 2006 and 2017 (n=188). Mean age was 19.4 years (SD 13.2). The indication was stenosis (45%), regurgitation (33%) and mixed (22%). Pre-stenting was performed in all except the initial four patients. In stenotic lesions the peak gradient was 36 mmHg PIG (SD 12.0) after 11 years and in regurgitant lesions the maximal regurgitation was 2/4. Stent fractures were observed in 8.6%; only one grade III fracture required redo PPVI. Surgical removal was carried out in seven (3.7%), redo PPVI in five (2.7%). Endocarditis was diagnosed in 19 (10.2%) patients at a median of 2.3 years (0.7-8.8) after Melody implantation. Three were surgically removed early because of persistent infection, 16 were sterilised; six required replacement (three surgical, three redo PPVI). There were no valve- or procedure-related deaths.
CONCLUSIONS: The Melody valve shows a good preserved leaflet function up to 11 years after implantation. The main reason for graft failure was endocarditis, although in half of those patients no reintervention was needed. After pre-stenting, stent fractures led very exceptionally to reintervention.

Entities:  

Mesh:

Year:  2018        PMID: 29957592     DOI: 10.4244/EIJ-D-18-00054

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  3 in total

1.  The Sapien valve provides enough grip to be implanted in pulmonary position without a pre-stent.

Authors:  Daniel Tanase; Stanimir Georgiev; Andreas Eicken; Peter Ewert
Journal:  Cardiovasc Diagn Ther       Date:  2019-10

2.  Long-Term Outcomes After Melody Transcatheter Pulmonary Valve Replacement in the US Investigational Device Exemption Trial.

Authors:  Thomas K Jones; Doff B McElhinney; Julie A Vincent; William E Hellenbrand; John P Cheatham; Darren P Berman; Evan M Zahn; Danyal M Khan; John F Rhodes; Shicheng Weng; Lisa J Bergersen
Journal:  Circ Cardiovasc Interv       Date:  2021-12-21       Impact factor: 6.546

3.  Right Heart Failure in a Patient with Critical Pulmonary Stenosis, Absent Right Pulmonary Artery, and Lung Cancer.

Authors:  Arthur Iturriagagoitia; Marc Vanderheyden; Werner Budts; Piet Vercauter
Journal:  Am J Case Rep       Date:  2022-08-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.